The Score: Novo Nordisk, Oracle, Netflix, and More Stocks That Defined the Week
Here are some of the major companies whose stocks moved on the week’s news.
Novo Nordisk stock surges 7% after Ozempic maker’s latest weight loss drug shows promise
The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...
U.K. pharma group criticizes Novo over patient payments: report
Novo Nordisk (NVO) has reportedly been criticized by a U.K. pharma industry group for mischaracterizing certain payments to ...
pharmaphorum7d
Changing Faces: Pharma and biotech November-December 2024
Pfizer named Dr Chris Boshoff as CSO and president of R&D, effective 1st January 2025. Boshoff, previously Pfizer’s chief ...
PMLiVE8d
Novo Nordisk and Valo Health expand alliance for cardiometabolic diseases
Novo Nordisk and Valo Health have expanded their agreement to discover and develop new treatments for type 2 diabetes, ...
24/7 Wall St10d
Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
Daily12d
Novo Nordisk, Valo Health expand collaboration to discover, develop novel treatments for cardiometabolic diseases
Lexington: Novo Nordisk A/S and Valo Health, Inc. have announced they have entered into an expanded agreement to discover and ...
Nasdaq14d
Pharma Stock Roundup: FDA Updates for JNJ, GSK, PFE, NVO's Expanded Deal
Novo Nordisk announced that it is expanding its previous collaboration with Valo Health to discover and develop novel treatments for cardiometabolic diseases. The companies had originally signed ...
Pharmabiz14d
Novo Nordisk and Valo Health expand collaboration to discover and develop novel treatments for cardiometabolic diseases
Novo Nordisk A/S, a leading global healthcare company, and Valo Health, Inc. announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 ...